Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.62 |
| ▸ | CTSL | P07711 | 3/20 | 0.61 |
| ▸ | CTSB | P07858 | 2/20 | 0.61 |
| ▸ | CTSS | P25774 | 2/20 | 0.61 |
| ▸ | CTSK | P43235 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.58 |
| ▸ | CTSG | P08311 | 1/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7490981 | 1.00 | TACR1 (0.62) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL4980616 | 1.00 | TACR1 (0.62) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL6489247 | 0.92 | TACR1 (0.55) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL7267663 | 0.92 | TACR1 (0.55) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL7269586 | 0.90 | HDAC8 (0.59) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL9754234 | 0.88 | CTSL (0.57) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL11145746 | 0.88 | CTSL (0.58) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL7493291 | 0.87 | CTSG (0.55) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL7487532 | 0.87 | CTSG (0.55) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL7487527 | 0.87 | CTSG (0.55) | TACR1CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0969000-B1 | Process for reducing alpha-amino ketones | KANEKA CORP (JP) | 2002-12-04 | — | — | EP | claimed |
| US-6255522-B1 | USING AS REDUCING AGENT A REACTION PRODUCT OF ORGANOALUMINUM COMPOUND, SULFONATE AND ALCOHOL | KANEKA CORPORATION (JP) | 2001-07-03 | — | — | US | claimed |
| EP-0969000-A1 | PROCESS FOR REDUCING $G(a)-AMINO KETONES | KANEKA CORPORATION (JP) | 2000-01-05 | — | — | EP | claimed |
| US-7157495-B2 | Hexahydrofuro[2,3-B]furan-3-YL-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2007-01-02 | — | — | US | disclosed |
| US-6924397-B2 | Process for the preparation of α-chloroketones from alkyl esters | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-20050090670-A1 | PROCESS FOR THE PREPARATION OF ALPHA-CHLOROKETONES FROM ALKYL ESTERS | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-28 | — | — | US | disclosed |
| EP-0633881-B1 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS | NARHEX LTD (HK) | 2003-10-29 | — | — | EP | disclosed |
| EP-0969000-B1 | Process for reducing alpha-amino ketones | KANEKA CORP (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-0754669-B1 | PROCESSES FOR PRODUCING ALPHA-HALO KETONES, ALPHA-HALOHYDRINS AND EPOXIDES | KANEKA CORP (JP) | 2001-10-31 | — | — | EP | disclosed |
| US-6255522-B1 | USING AS REDUCING AGENT A REACTION PRODUCT OF ORGANOALUMINUM COMPOUND, SULFONATE AND ALCOHOL | KANEKA CORPORATION (JP) | 2001-07-03 | — | — | US | disclosed |
| EP-0969000-A1 | PROCESS FOR REDUCING $G(a)-AMINO KETONES | KANEKA CORPORATION (JP) | 2000-01-05 | — | — | EP | disclosed |
| US-5902887-A | Process for producing 3-amino-2-oxo-1-halogenopropane derivatives | AJINOMOTO CO., INC. (JP) | 1999-05-11 | — | — | US | disclosed |
| EP-0754669-A1 | PROCESSES FOR PRODUCING ALPHA-HALO KETONES, ALPHA-HALOHYDRINS AND EPOXIDES | KANEKA CORPORATION (JP) | 1997-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090670-A1 | PROCESS FOR THE PREPARATION OF ALPHA-CHLOROKETONES FROM ALKYL ESTERS | KHK, BCKDK, STS | TACR1 3953/4885CTSL 418/4885CTSB 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.